false --09-30 0001649989 0001649989 2024-03-07 2024-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 7, 2024

 

 

 

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-37759 38-3982704
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer Identification No.)

 

485 Route 1 South

Building F, Suite 320

Iselin, New Jersey

08830
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (609) 619-3990

 

                                                                                    

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which
Registered
Common Stock   OTLK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

At the 2024 Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders of Outlook Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 425,000,000 to 1,200,000,000 shares. The increase in the authorized number of shares of the Company’s common stock was effected pursuant to a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on March 7, 2024 and was effective as of such date. The foregoing description is qualified in its entirety by the Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 5.07Submission of Matters to a Vote of Security Holders

 

At the Annual Meeting held on March 7, 2024, the Company’s stockholders voted on eight proposals, each of which is described in more detail in the Company’s proxy statement on Schedule 14A filed with the Securities and Exchange Commission on February 8, 2024 (the “Proxy Statement”). Of the 260,257,517 shares of the Company’s common stock outstanding as of the record date, 194,030,258 shares, or approximately 74.6%, were present or represented by proxy at the Annual Meeting.

 

The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each such matter.

 

Proposal 1. Stockholders elected each of the following nominees to serve as Class II directors on the Company’s Board of Directors (the “Board”) until the Company’s 2027 Annual Meeting of Stockholders or until his or her successor has been duly elected and qualified. The voting results for such nominees were as follows:

 

Director Name  Votes For    Votes Withheld   Broker Non-
Votes
 
Gerd Auffarth, M.D.   122,406,604    7,573,738    64,049,916 
Julia A. Haller, M.D.   126,307,671    4,173,076    63,549,511 
Andong Huang   128,730,972    1,749,775    63,549,511 
Lawrence A. Kenyon   125,464,513    4,524,055    64,041,690 

 

Proposal 2. Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock in a private placement of shares of common stock and accompanying warrants at less than the “minimum price” under Nasdaq Listing Rule 5635. The voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-
Votes
 
 123,467,622    6,224,132    788,993    63,549,511 

 

Proposal 3. Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock upon the conversion of an outstanding convertible note at less than the “minimum price” under Nasdaq Listing Rule 5635, if required pursuant to the terms of the convertible note. The voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-
Votes
 
 123,394,516    6,301,788    784,443    63,549,511 

 

Proposal 4. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of its common stock authorized for issuance from 425,000,000 to 1,200,000,000 shares. The voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-
Votes
 
 123,007,844    6,742,110    730,793    63,549,511 

 

 

 

 

Proposal 5. Stockholders did not approve the amendment of the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. The voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-
Votes
 
 125,438,289    3,598,772    1,443,686    63,549,511 

 

Proposal 6. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock, and a reduction in the number of authorized shares of common stock, at a ratio of 1-for-10 to 1-for-30. The voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-
Votes
 
 174,074,763    15,567,247    4,388,248     N/A  

 

Proposal 7. Stockholders ratified the selection by the Audit Committee of the Board of KPMG LLP as the Company’s independent registered public accounting firm for its fiscal year ending September 30, 2024. The voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-
Votes
 
 188,948,425    3,717,708    1,364,124     N/A  

 

Proposal 8. Stockholders approved a non-binding advisory vote on the compensation of the Company’s named executive officers. The voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-
Votes
 
 126,964,912    3,193,076    322,759    63,549,511 

 

Item 9.01Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
3.1   Certificate of Amendment of the Amended and Restated Certificate of Incorporation
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Outlook Therapeutics, Inc.
   
Date: March 7, 2024 By: /s/ Lawrence A. Kenyon
    Lawrence A. Kenyon
    Chief Financial Officer

 

 

 

 

 

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF
INCORPORATION OF OUTLOOK THERAPEUTICS, INC.

 

Outlook Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that:

 

First: The name of the Company is Outlook Therapeutics, Inc. (the “Company”).

 

Second: The date of the filing the original Certificate of Incorporation of this Company with the Secretary of State of the State of Delaware was October 22, 2015 and the date of filing of the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware was May 18, 2016.

 

Third: Paragraph A of ARTICLE IV of the Company’s Amended and Restated Certificate of Incorporation be, and it hereby is, amended and restated to read in its entirety as follows:

 

A. The Company is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Company is authorized to issue is one billion two hundred and ten million (1,210,000,000) shares. One billion two hundred million (1,200,000,000) shares shall be Common Stock, each having a par value of one cent ($0.01). Ten million (10,000,000) shares shall be Preferred Stock, each having a par value of one cent ($0.01).”

 

Fourth: The foregoing amendment was submitted to the stockholders of the Company for their approval, and was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

 

In Witness Whereof, Outlook Therapeutics, Inc. has caused this Certificate of Amendment to be signed by its Chief Financial Officer, Treasurer and Secretary this 7th day of March, 2024.

 

  Outlook Therapeutics, Inc.
   
   
  By: /s/ Lawrence A. Kenyon
    Lawrence A Kenyon
    Chief Financial Officer, Treasurer and Secretary